Pre-existing TCR clones drive major pathological responses in HNSCC patients treated with dual immune checkpoint inhibitors

Key Points

• The research aims to understand how pre-existing TCR clones influence responses in HNSCC patients receiving dual immune checkpoint inhibitors.
• Evaluated patient responses to dual immune checkpoint inhibitors in HNSCC.
• Analyzed clonal dynamics of pre-existing TCRs.
• Employed TRS-integrated TAI to assess therapeutic efficacy.
• Observed major pathological responses linked to pre-existing TCR clones.
• Noted successful therapy depends on the adaptation of tumor-reactive super-expanders.
• Predicted therapeutic outcomes using high-throughput clonal dynamics framework.